Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of adding aprepitant to prophylactic antiemetic regimen in moderate emetogenic chemotherapy
IRCT20191103045317N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Shahid Beheshti University of Medical Sciences. Started Dec 2018; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on IRCT20191103045317N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191103045317N1.